158 related articles for article (PubMed ID: 36380144)
1. Valemetostat Tosilate: First Approval.
Keam SJ
Drugs; 2022 Nov; 82(16):1621-1627. PubMed ID: 36380144
[TBL] [Abstract][Full Text] [Related]
2. Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma.
Dou F; Tian Z; Yang X; Li J; Wang R; Gao J
Drug Discov Ther; 2022 Dec; 16(6):297-299. PubMed ID: 36310058
[TBL] [Abstract][Full Text] [Related]
3. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.
Izutsu K; Makita S; Nosaka K; Yoshimitsu M; Utsunomiya A; Kusumoto S; Morishima S; Tsukasaki K; Kawamata T; Ono T; Rai S; Katsuya H; Ishikawa J; Yamada H; Kato K; Tachibana M; Kakurai Y; Adachi N; Tobinai K; Yonekura K; Ishitsuka K
Blood; 2023 Mar; 141(10):1159-1168. PubMed ID: 36150143
[TBL] [Abstract][Full Text] [Related]
4. Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients.
Bagnato G; Stefoni V; Broccoli A; Argnani L; Pellegrini C; Casadei B; Bonifazi F; Zinzani PL
Mediterr J Hematol Infect Dis; 2024; 16(1):e2024004. PubMed ID: 38223480
[TBL] [Abstract][Full Text] [Related]
5. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
6. Umbralisib: First Approval.
Dhillon S; Keam SJ
Drugs; 2021 May; 81(7):857-866. PubMed ID: 33797740
[TBL] [Abstract][Full Text] [Related]
7. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
Yamagishi M; Hori M; Fujikawa D; Ohsugi T; Honma D; Adachi N; Katano H; Hishima T; Kobayashi S; Nakano K; Nakashima M; Iwanaga M; Utsunomiya A; Tanaka Y; Okada S; Tsukasaki K; Tobinai K; Araki K; Watanabe T; Uchimaru K
Cell Rep; 2019 Nov; 29(8):2321-2337.e7. PubMed ID: 31747604
[TBL] [Abstract][Full Text] [Related]
8. Idelalisib: first global approval.
Markham A
Drugs; 2014 Sep; 74(14):1701-7. PubMed ID: 25187123
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
10. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
11. [Adult T-cell leukemia/lymphoma: progress in understanding of pathogenesis and treatment].
Yoshimitsu M
Rinsho Ketsueki; 2023; 64(6):497-503. PubMed ID: 37407474
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax: First Global Approval.
Deeks ED
Drugs; 2016 Jun; 76(9):979-87. PubMed ID: 27260335
[TBL] [Abstract][Full Text] [Related]
13. Mogamulizumab: first global approval.
Subramaniam JM; Whiteside G; McKeage K; Croxtall JC
Drugs; 2012 Jun; 72(9):1293-8. PubMed ID: 22686619
[TBL] [Abstract][Full Text] [Related]
14. Tazemetostat for the treatment of multiple types of hematological malignancies and solid tumors.
Marsh S; Jimeno A
Drugs Today (Barc); 2020 Jun; 56(6):377-387. PubMed ID: 32525136
[TBL] [Abstract][Full Text] [Related]
15. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
[TBL] [Abstract][Full Text] [Related]
16. Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.
Xia J; Li J; Tian L; Ren X; Liu C; Liang C
J Med Chem; 2022 May; 65(10):7016-7043. PubMed ID: 35531606
[TBL] [Abstract][Full Text] [Related]
17. Lymphoma study group of JCOG.
Tsukasaki K; Tobinai K; Hotta T; Shimoyama M
Jpn J Clin Oncol; 2012 Feb; 42(2):85-95. PubMed ID: 22147803
[TBL] [Abstract][Full Text] [Related]
18. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
[TBL] [Abstract][Full Text] [Related]
19. [Histone deacetylase inhibitors in the treatment of hematological malignancies].
Lemal R; Ravinet A; Moluçon-Chabrot C; Bay JO; Guièze R
Bull Cancer; 2011 Aug; 98(8):867-78. PubMed ID: 21827981
[TBL] [Abstract][Full Text] [Related]
20. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
